Back to today’s briefing

Story perspectives

Repare Therapeutics Pauses Development, Prioritizes Promising Assets

1/8/2025

40 9

Summary

Story summary

Repare Therapeutics is sharpening its focus by pausing the development of Lunre+Camo and actively seeking partners for additional funding. With a robust $153 million in cash, the company is set to extend its financial runway to mid-2027, prioritizing the promising phase 1 assets RP-1664 and RP-3467 to address critical patient needs.

1 of 1

Story summary

Repare Therapeutics is sharpening its focus by pausing the development of Lunre+Camo and actively seeking partners for additional funding. With a robust $153 million in cash, the company is set to extend its financial runway to mid-2027, prioritizing the promising phase 1 assets RP-1664 and RP-3467 to address critical patient needs.